Triple therapy shows promise for controlling liver cancer

This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (PD-1/PD-L1 inhibitors), and targeted drugs (VEGF-TKI or bevacizumab)—in 941 people with intermediate-stage liver cancer. The goal was to see if this triple therapy could delay cancer growth and improve survival. Participants had not received prior systemic therapy. The results help doctors understand how to better control the disease, but ongoing management is still needed.